Voruciclib - MEI Pharma

Drug Profile

Voruciclib - MEI Pharma

Alternative Names: P-1446A-05; P1446; Voruciclib

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Piramal Life Sciences
  • Developer Dana-Farber Cancer Institute; MEI Pharma; Norris Cotton Cancer Center; Piramal Enterprises
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diffuse large B cell lymphoma
  • No development reported Cancer; Chronic lymphocytic leukaemia; Malignant melanoma

Most Recent Events

  • 28 Nov 2017 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in USA (PO)
  • 08 Nov 2017 MEI Pharma plans a phase I/II trial for B-cell leukaemia (Monotherapy, Second-line therapy or greater) in the second quarter of 2018
  • 06 Nov 2017 MEI Pharma plans a clinical trial for B-cell leukaemia (Combination therapy with venetoclax, Second-line therapy or greater) in the second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top